Theo Roth

Dr. Theo Roth was the founding CSO and is a scientific co-founder of Arsenal Biosciences. He has considerable experience in immunology and microscopy through a predoctoral fellowship at the NIH, and in biomedical informatics and systems biology through his undergraduate and masters work at Stanford University.

During his MD/PhD training at UCSF, he developed non-viral genome targeting, a new efficient method for large scale genetic engineering of primary human immune cells without the need for complex viral vectors. He further developed robust methods of pooled knock-in screening, enabling rapid discovery of synthetic sequences to re-wire T cell genomes. This work has led to pre-clinical development of novel cell therapies for both autoimmune disease and solid tumors. He is currently completing a residency in Clinical Pathology at Stanford University.